Historical Valuation
ARS Pharmaceuticals Inc (SPRY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.92 is considered Undervalued compared with the five-year average of -11.43. The fair price of ARS Pharmaceuticals Inc (SPRY) is between 176.68 to 189.49 according to relative valuation methord. Compared to the current price of 13.06 USD , ARS Pharmaceuticals Inc is Undervalued By 92.61%.
Relative Value
Fair Zone
176.68-189.49
Current Price：13.06
92.61%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
ARS Pharmaceuticals Inc (SPRY) has a current Price-to-Book (P/B) ratio of 7.69. Compared to its 3-year average P/B ratio of 4.46 , the current P/B ratio is approximately 72.41% higher. Relative to its 5-year average P/B ratio of 4.07, the current P/B ratio is about 89.15% higher. ARS Pharmaceuticals Inc (SPRY) has a Forward Free Cash Flow (FCF) yield of approximately -7.57%. Compared to its 3-year average FCF yield of -6.46%, the current FCF yield is approximately 17.25% lower. Relative to its 5-year average FCF yield of -6.33% , the current FCF yield is about 19.63% lower.
P/B
Median3y
4.46
Median5y
4.07
FCF Yield
Median3y
-6.46
Median5y
-6.33
Competitors Valuation Multiple
AI Analysis for SPRY
The average P/S ratio for SPRY competitors is 382.76, providing a benchmark for relative valuation. ARS Pharmaceuticals Inc Corp (SPRY.O) exhibits a P/S ratio of 6.92, which is -98.19% above the industry average. Given its robust revenue growth of 1471.62%, this premium appears sustainable.
Performance Decomposition
AI Analysis for SPRY
1Y
3Y
5Y
Market capitalization of SPRY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SPRY in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SPRY currently overvalued or undervalued?
ARS Pharmaceuticals Inc (SPRY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.92 is considered Undervalued compared with the five-year average of -11.43. The fair price of ARS Pharmaceuticals Inc (SPRY) is between 176.68 to 189.49 according to relative valuation methord. Compared to the current price of 13.06 USD , ARS Pharmaceuticals Inc is Undervalued By 92.61% .
What is ARS Pharmaceuticals Inc (SPRY) fair value?
SPRY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of ARS Pharmaceuticals Inc (SPRY) is between 176.68 to 189.49 according to relative valuation methord.
How does SPRY's valuation metrics compare to the industry average?
The average P/S ratio for SPRY's competitors is 382.76, providing a benchmark for relative valuation. ARS Pharmaceuticals Inc Corp (SPRY) exhibits a P/S ratio of 6.92, which is -98.19% above the industry average. Given its robust revenue growth of 1471.62%, this premium appears sustainable.
What is the current P/B ratio for ARS Pharmaceuticals Inc (SPRY) as of Jan 11 2026?
As of Jan 11 2026, ARS Pharmaceuticals Inc (SPRY) has a P/B ratio of 7.69. This indicates that the market values SPRY at 7.69 times its book value.
What is the current FCF Yield for ARS Pharmaceuticals Inc (SPRY) as of Jan 11 2026?
As of Jan 11 2026, ARS Pharmaceuticals Inc (SPRY) has a FCF Yield of -7.57%. This means that for every dollar of ARS Pharmaceuticals Inc’s market capitalization, the company generates -7.57 cents in free cash flow.
What is the current Forward P/E ratio for ARS Pharmaceuticals Inc (SPRY) as of Jan 11 2026?
As of Jan 11 2026, ARS Pharmaceuticals Inc (SPRY) has a Forward P/E ratio of -7.61. This means the market is willing to pay $-7.61 for every dollar of ARS Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for ARS Pharmaceuticals Inc (SPRY) as of Jan 11 2026?
As of Jan 11 2026, ARS Pharmaceuticals Inc (SPRY) has a Forward P/S ratio of 6.92. This means the market is valuing SPRY at $6.92 for every dollar of expected revenue over the next 12 months.